Evidence map›Paper›PMID 40830965›Full record

ArticleHuman vaccines & immunotherapeutics2025

Prospective study of safety, immunogenicity, and efficacy of inactivated COVID-19 vaccine in tuberous sclerosis complex children on sirolimus.

Sufang Lin, Xia Zhao, Lin Li, Qiru Su, Weiwei Long, Xiaoqin Tian, Jinghua Ye, Bixia Yuan, Yan Hu, Jianxiang Liao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Autophagy andFrontiers in cellular and infection microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sufang LinDepartment of Neurology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.ORCID 0000-0001-5728-1462
Xia ZhaoDepartment of Neurology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.ORCID 0000-0002-9750-367X
Lin LiDepartment of Epilepsy Surgery, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.ORCID 0000-0002-2310-2398
Qiru SuDepartment of Clinical Research, Shenzhen Children's Hospital, Shenzhen, Guangdong, China.
Weiwei LongDepartment of Neurology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.
Xiaoqin TianDepartment of Neurology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.
Jinghua YeDepartment of Neurology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.
Bixia YuanDepartment of Neurology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.
Yan HuDepartment of Neurology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.
Jianxiang LiaoDepartment of Neurology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.ORCID 0000-0001-9769-3365
Hongbing ZhangDepartment of Physiology, State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0001-6291-1027

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While sirolimus is widely used in tuberous sclerosis complex (TSC), its impact on coronavirus disease 2019 (COVID-19) vaccination remains unclear. To evaluate the safety, immunogenicity, and efficacy of inactivated COVID-19 vaccine on the children with TSC on sirolimus, we conducted a prospective cohort study (July 1

Indexed as

COVID-19COVID-19 VaccinesImmunogenicity, VaccineImmunosuppressive AgentsSirolimusTuberous SclerosisAdolescentAntibodies, NeutralizingAntibodies, ViralChildChild, PreschoolFemaleHumansInfantMaleProspective StudiesAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunosuppressive AgentsSARS-CoV-2 inactivated vaccinesSirolimusVaccines, InactivatedCOVID-19efficacyimmunogenicitysirolimustuberous sclerosis complexvaccine

Identifiers

PMID40830965
PMCPMC12369617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.